Doximity (DOCS) just paired a revenue beat with higher fiscal 2027 guidance, while rolling out new AI tools like DoseCheck and deepening health system and pharma relationships, giving investors fresh data on both growth and profitability trade offs.
Despite the solid product and guidance updates, Doximity’s 1-year total shareholder return declined 40.12%, even as the 90-day share price return gained 26.84% and the 30-day move rose 6.59%. This suggests some momentum has started to rebuild after a year-to-date share price return that fell 24.90%.
Track how Doximity’s AI push compares with peers by scanning 35 healthcare AI stocks that are already seeing strong interest in clinical decision support and digital health workflows.
Doximity’s sharp rebound over the last three months contrasts with a much weaker one-year return, which leaves you with a simple fork in the road. Is this the reset that justifies paying up now, or a setup to wait on price and valuation work next?
Most Popular Narrative: 3.5% Undervalued
Doximity’s most followed narrative pegs fair value at $33.70 against the last close of $32.51. This leaves a small valuation gap that keeps the focus squarely on how its physician network and AI tools might convert usage into more durable economics.
What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not a private practice.
See why 10 investors see Doximity as 4% undervalued.
Result: Fair Value of $33.70 (UNDERVALUED)
Still, the Doximity story can break if physician engagement proves less monetizable than hoped or if rival clinical AI tools pull users and budgets away.
Find out about the key risks to this Doximity narrative.
Next Steps
If this mix of optimism and concern around Doximity feels familiar, use it as a prompt to check the numbers yourself and move quickly. Then round out your view by weighing both sides of the story with the 2 key rewards and 1 important warning sign.
Looking for more Doximity-sized investment ideas?
If Doximity has your attention, do not stop here. Broaden your watchlist with data driven ideas that could support your next step.
- Explore resilient compounding potential by focusing on businesses with strong cash and low leverage through the list of solid balance sheet and fundamentals (25 results).
- Consider quality at a sensible entry point by scanning the 38 high quality undervalued stocks that pair solid fundamentals with discounted pricing.
- Look for potential future leaders early by reviewing the 19 high quality undiscovered gems before the wider market starts paying close attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com